Stock Scorecard



Stock Summary for Achieve Life Sciences Inc (ACHV) - $4.53 as of 11/20/2024 7:40:51 PM EST

Total Score

10 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ACHV

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ACHV

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ACHV

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ACHV

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ACHV (22 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for ACHV

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Turning Point Brands ( NYSE:TPB ) 11/14/2024 12:53:00 PM
Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting 10/23/2024 12:00:00 PM
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline 10/16/2024 12:00:00 PM
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline - Achieve Life Sciences ( NASDAQ:ACHV ) 10/16/2024 12:00:00 PM
Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs - Achieve Life Sciences ( NASDAQ:ACHV ) 10/1/2024 12:45:00 PM
Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs 10/1/2024 12:45:00 PM
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors 8/26/2024 8:30:00 PM
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors - Achieve Life Sciences ( NASDAQ:ACHV ) 8/26/2024 8:30:00 PM
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence 7/31/2024 12:00:00 PM
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank 7/29/2024 12:00:00 PM

Financial Details for ACHV

Company Overview

Ticker ACHV
Company Name Achieve Life Sciences Inc
Country USA
Description Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Sector Name LIFE SCIENCES
Industry Name IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 4.53
Price 4 Years Ago 8.10
Last Day Price Updated 11/20/2024 7:40:51 PM EST
Last Day Volume 152,336
Average Daily Volume 106,449
52-Week High 5.98
52-Week Low 3.03
Last Price to 52 Week Low 49.50%

Valuation Measures

Trailing PE N/A
Industry PE 44.80
Sector PE 40.32
5-Year Average PE -2.38
Free Cash Flow Ratio 3.62
Industry Free Cash Flow Ratio 41.60
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 6.78
Total Cash Per Share 1.25
Book Value Per Share Most Recent Quarter 0.91
Price to Book Ratio 4.76
Industry Price to Book Ratio 9.11
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 8.48
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 34,389,900
Market Capitalization 155,786,247
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.62%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 29.60%
Reported EPS 12 Trailing Months -1.12
Reported EPS Past Year -0.87
Reported EPS Prior Year -1.53
Net Income Twelve Trailing Months -32,943,000
Net Income Past Year -29,815,000
Net Income Prior Year -42,350,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 42,900,000
Total Cash Past Year 15,500,000
Total Cash Prior Year 24,800,000
Net Cash Position Most Recent Quarter 33,077,000
Net Cash Position Past Year -1,157,000
Long Term Debt Past Year 16,657,000
Long Term Debt Prior Year 16,004,000
Total Debt Most Recent Quarter 9,823,000
Equity to Debt Ratio Past Year -0.10
Equity to Debt Ratio Most Recent Quarter 0.76
Total Stockholder Equity Past Year -1,448,000
Total Stockholder Equity Prior Year 8,303,000
Total Stockholder Equity Most Recent Quarter 31,378,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -24,966,000
Free Cash Flow Per Share Twelve Trailing Months -0.73
Free Cash Flow Past Year -24,500,000
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.09
MACD Signal -0.03
20-Day Bollinger Lower Band 4.08
20-Day Bollinger Middle Band 4.62
20-Day Bollinger Upper Band 5.16
Beta 1.58
RSI 33.60
50-Day SMA 4.60
150-Day SMA 5.12
200-Day SMA 6.17

System

Modified 11/20/2024 4:24:57 PM EST